Research

Hormonal

Coadministration of tirzepatide and SGLT2 inhibitors in Type 1 Diabetes Mellitus patients significantly increases the risk of severe euglycemic diabetic ketoacidosis (euDKA), potentially requiring mechanical ventilation.

If you have Type 1 Diabetes, do not take Tirzepatide or SGLT2 inhibitors together without extreme caution and specialist oversight. Monitor ketones daily, especially if you feel nauseous or vomit, as blood sugar may remain normal while dangerous acidosis builds up.

LimitedSupportsLOW confidence
This case highlights the synergistic metabolic risks of coadministering tirzepatide and an SGLT2 inhibitor (empagliflozin) in patients with T1DM... The severity of acidosis necessitated intubation and intravenous bicarbonate therapy.
M. Habib Amin Malik et al. · Clinical Case Reports · 2026

Why this rating

Based on a single case report; lacks controlled trial data but provides strong mechanistic plausibility.

Source

Severe Euglycemic Diabetic Ketoacidosis Requiring Intubation After Tirzepatide and <scp>SGLT2</scp> Inhibitor Coadministration in a Patient With Type 1 Diabetes Mellitus From a Large Tertiary Care Centre in Karachi, Pakistan: A Case Report and Brief Review of the Literature

M. Habib Amin Malik et al. · Clinical Case Reports · 2026

DOI 10.1002/ccr3.71929

case_report · n=1Cited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →